Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 02, 2019 09:00 ET | Source: Noxopharm

Positive DARRT-1 Data in Late-Stage Prostate Cancer

Clinical responses point to the NOX66 DARRT treatment regimen as a potentially major new treatment option for men with late-stage prostate cancerPositive results trigger planning for proposed pivotal...
November 06, 2019 09:26 ET | Source: Noxopharm

Noxopharm Announces Appointment of Chief Commercial Officer

Noxopharm has appointed Mr Alexander Hunter as Chief Commercial OfficerMr Hunter is an experienced corporate finance and business executive with a background in high growth listed company operations...
October 18, 2019 09:13 ET | Source: Noxopharm

Potential for Fundamental Change in the Treatment of Brain Cancer

Noxopharm commences a research program pursuing a novel approach to the treatment of glioblastoma multiforme (GBM), the most common and aggressive form of brain cancerBased on recent international...
September 17, 2019 11:01 ET | Source: Noxopharm

Veyonda® and Radiotherapy Profiled at Key Oncology Meeting

Research relating to Veyonda® in the treatment of advanced prostate cancer is to be included in a key Australian oncology meetingBoth Noxopharm and independent investigators have abstracts...
August 21, 2019 08:12 ET | Source: Noxopharm

Pre-Clinical Evidence Confirms Veyonda® Abscopal Effect

Veyonda® is being developed as a transformative anti-cancer treatment (DARRT) in combination with radiotherapy to produce off-target responses known as an abscopal effectPre-clinical studies now...
July 29, 2019 08:00 ET | Source: Noxopharm

Appendix 4C– June 2019 Quarter

Positive results from two prostate cancer trialsPhase 2 trial design gaining momentumInvestigational New Drug Application to be submitted to FDA in Q3 2019Pipeline developing based on drug discovery...